Related Experiment Video
Updated: Aug 5, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
Cysteine Re-bridging Using Divinyl Pyrimidine Reagents for the Generation of Antibody-Drug Conjugates
Thomas Wharton1, Sona Krajcovicova1, David R Spring2
1Yusuf Hamied Department of Chemistry, Lensfield Road, Cambridge, CB2 1EW, UK.
Abstract:
Antibody-drug conjugates (ADCs) are a powerful form of targeted therapy that can deliver drugs with a high level of selectivity towards a specific cell type, reducing off-target effects and increasing the therapeutic window compared to small-molecule therapeutics. However, creating ADCs that are stable, homogeneous, and with a controlled drug-to-antibody ratio (DAR) remains a significant challenge. Divinyl pyrimidine (DVP) reagents were developed as a method to irreversibly conjugate linker-payloads onto native antibodies to generate stable ADCs and antibody-probe systems with a precise drug-to-antibody ratio (DAR) of 4. This protocol describes how to conjugate DVPs to antibodies and methods for ADC characterization.
Related Concept Videos
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
Phase II Reactions: Miscellaneous Conjugation Reactions
A key example involves the conjugation of cyanide ions, which impair cellular respiration and alter hemoglobin into non-oxygen-carrying cyanmethemoglobin. To neutralize this threat, a sulfur atom from thiosulphate is transferred to the cyanide ion, catalyzed by the enzyme rhodanese, resulting in an inactive compound called thiocyanate. The production of...

